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ABSTRACT The structure of a crystal complex of the
chemically synthesized protease of human immunodeficiency
virus 1 with a heptapeptide-derived inhibitor bound in the
active site has been determined. The sequence of the inhibitor
JG-365 is Ac-Ser-Leu-Asn-Phe-#[CH(OH)CH2N]-Pro-Ile-Val-
OMe; the K; is 0.24 nM. The hydroxyethylamine moiety, in
place of the normal scissile bond of the substrate, is believed to
mimic a tetrahedral reaction intermediate. The structure of the
complex has been rermed to an R factor of 0.146 at 2.4A
resolution by using restrained least squares with rms deviations
in bond lengths of 0.02 A and bond angles of 4'. The bound
inhibitor diastereomer has the S configuration at the hydroxy-
ethylamine chiral carbon, and the hydroxyl group is positioned
between the active site aspartate carboxyl groups within hy-
drogen bonding distance. Comparison of this structure with a
reduced peptide bond inhibitor-protease complex indicates
that these contacts confer the exceptional binding strength of
JG-365.
Reverse transcriptase, integrase, and protease are the three
virally encoded enzymes necessary for replication of human
immunodeficiency virus 1 (HIV-1), so each is a potential
target for drug design. Rational design of drugs directed
against AIDS would be greatly facilitated by knowledge of
the three-dimensional structures of the target molecules, yet
the protease is the only one of these enzymes for which the
structure of the native form (1-3) or of an inhibitor complex
(4) is known. The protease is a member of the well-
characterized family of aspartic proteases, which also in-
cludes mammalian enzymes such as renin, pepsin, and chy-
mosin. Whereas cell-encoded aspartic proteases are mono-
mers with distinct amino and carboxyl domains, the retroviral
proteases are dimers of identical subunits that are analogous
to these domains (5). The function of the HIV-1 protease is
to cleave the translated viral gag-pol polyprotein into discrete
components. Without protease activity, the viral particle
remains noninfective (6, 7) and this property makes the
protease an attractive candidate for therapeutic drug design
against AIDS (8-14).
Inhibitors -of aspartic proteases have been developed as
potential pharmaceutical agents for modulating the biological
processes catalyzed by this class of enzymes (15, 16). Most
efforts in recent years have been directed toward developing
antihypertensive drugs that inhibit the aspartic protease renin
(17) and the principles that were discovered have greatly
facilitated the design of inhibitors of HIV-1 protease. The
best inhibitors are derived from substrate sequences by
replacing the dipeptide cleavage site with stable analogs of
reaction pathway intermediates (18-22). Extremely potent
inhibitors of HIV-1 protease contain a hydroxyethylamine
(HEA) linkage, which is believed to mimic a tetrahedral
intermediate of substrate hydrolysis (14, 22). These com-
pounds have been shown to effectively inhibit processing of
a synthetic substrate (14, 22) and of the HIV-1 gag-pol
polyprotein (14) in vitro. It has also been demonstrated
directly that several of the protease inhibitors have antiviral
activity in tissue cultures (12-14).
Herein we report the structure of a synthetic HIV-1
protease complexed with an HEA inhibitor, JG-365, and
compare it with a complex structure in which the reduced
peptide bond inhibitor MVT-101 was 3000 times less potent
(4). The results substantiate a previously proposed mecha-
nism of action for this class of enzymes (23) and have
implications for the design of other inhibitors of HIV-1
protease. Inhibitor JG-365, which has the sequence Ac-Ser-
Leu-Asn-Phe-qi[CH(OH)CH2N]-Pro-Ile-Val-OMe, was used
as a mixture of both the R and S diastereomers. The mixture
has a Ki of 0.66 nM against synthetic HIV-1 protease,
whereas the pure S diastereomer has a Ki of 0.24 nM (C. Q.
Sun and M. V. Toth, personal communication). MVT-101,
the reduced peptide bond inhibitor with the sequence Ac-
Thr-Ile-Nle-q(CH2NH)-Nle-Gln-Arg (where NMe is norleu-
cine), is used as a reference and has a K1 of 780 nM.
MATERIALS AND METHODS
HIV-1 [Aba67'95]protease (where Aba is L-a-amino-n-butyric
acid) was chemically synthesized as previously described
(24, 25). The sequence used was that of the SF2 isolate with
cysteines replaced by L-a-amino-n-butyric acid (2). The
inhibitor JG-365 was synthesized as described (22). The Ki
values were measured at pH 6.5 (22).
Crystals were grown by vapor diffusion using the hanging-
drop technique. Conditions in the reservoir were 55-60%
(vol/vol) saturated ammonium sulfate/-0.1 M sodium ace-
tate, pH 5.4. The protein concentration was -5 mg/mi. The
inhibitor was dissolved in dimethyl sulfoxide and diluted into
the protein sample to give a final inhibitor concentration of 9
mg/mi [9% (vol/vol) dimethyl sulfoxide]. The 6-/.l drops
consisted of 50% of this mixture and 50% of the protein-
inhibitor sample. Crystals grew at -230C in 3 days.
Abbreviations: HIV-1, human immunodeficiency virus 1; HEA,
hydroxyethylamine.
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The crystal used for data collection measured 0.06 x 0.1 x
0.4 mm and was mounted in a quartz capillary. Data were
collected using a Siemens area detector mounted on a three-
axis camera. The data extended to 2.4 A and were complete
to 2.5 A [5398 reflections with I > 1.5 a(I) from 10 to 2.4 A
were included in refinement]. The merging R factor on I was
8.9%.
The protease-JG-365 complex crystallized in space group
P212121 in a crystal form isomorphous to that of the protease-
MVT-101 complex (4). The unit-cell parameters were a =
51.2 A, b = 58.8 A, c = 62.0 A, a = 1f = y = 900, with a
homodimeric protein molecule and one inhibitor molecule in
the asymmetric unit. An initial difference electron density
map was generated by using phases calculated from atomic
coordinates of the protein alone from the structure of the
protease-MVT-101 complex. A model of JG-365 was built to
fit this density and the structure of the complex was refined
using the restrained least squares program PROFFT (26, 27) to
an R factor of 0.262. After 12 cycles ofrefinement the R factor
was lowered to 0.246 with an overall B of 12.0 A2. Electron
density maps were calculated with the coefficients (21FOI -
IFcI)ac and (IF01 - IFcI)ac (where F0 is the observed structure
factor, FC is the calculated structure factor, and ac is the
calculated phase). Refinement continued and solvent was
included with manual rebuilding interventions.
RESULTS
The final model includes 1516 protein atoms, 61 inhibitor
atoms, and 95 solvent atoms with the geometrical parameters
listed in Table 1. The R factor calculated at the completion of
refinement is 0.146, with a mean temperature factor for all
protein atoms of 15.1 A2. Monomer 1 is numbered from 1 to
99, monomer 2 is numbered from 101 to 199, and JG-365 is
numbered from 201 to 207. The first water listed in the
coordinates, water-301 [water-511 in the protease-MVT-101
complex (4)], is particularly important for binding the inhib-
itor. A comparison of this complex and the protease-MVT-
101 complex shows 34 solvent molecules common to both
structures, occupying positions within 1 A.
The conformation of the protease in the complex with
JG-365 can be considered the same as in the protease-MVT-
101 complex and is more compact than the native enzyme,
where the flaps are distant from the active site. The rms
Table 1. Summary of the geometrical parameters for the
structure of the HIV-1 protease-JG-365 complex
Target rms 8
(r (observed)
Distances, A
Bonded distances
Angle distances
Planar 1-4 distances
Planar groups, A
Chiral volume, A3
Nonbonded distances, A
Single torsion
Multiple torsion
Possible hydrogen bonds
Thermal restraints, A2
Main chain bond
Main chain angle
Side chain bond
Side chain angle
Torsion angles, deg
Planar
Staggered
Orthonormal
0.02
0.04
0.05
0.02
0.15
0.30
0.30
0.30
1.5
2.0
3.0
4.0
3
10
20
deviation between a carbons of the protein in the two
complexes is 0.37 A; for all atoms the difference is 0.43 A for
1363 pairs of atoms.
In the protease-JG-365 complex, the inhibitor is positioned
in a single orientation in the protease active site with the flaps
folded directly over it, protecting the inhibitor from bulk
solvent. The position and orientation of the inhibitor were
obvious from the first difference electron density map cal-
culated, and the electron density was further improved during
refinement (Fig. 1). The HEA hydroxyl group is nestled
between the side-chain carboxyl groups of the two active site
aspartates within hydrogen bonding distance. The bonding is
asymmetric with Asp-25 slightly closer than Asp-125. This
asymmetry and the distances are comparable to what was
found in other aspartyl protease-inhibitor complexes (23).
To verify the orientation of the inhibitor, residue-deleted
maps were used to fit it in the reverse direction. The reversed
inhibitor model, after refinement, did not fit well to its own(21Fol - IFCI)ac map, and the (IFol - IFJI) ac map showed
negative peaks where there were atoms and positive peaks
where there were not. Since the original inhibitor fit this map
quite well, our data give no evidence of inhibitor disorder in
this complex.
Although the inhibitor contained approximately equal
amounts of R and S configurations at the HEA chiral carbon
(22), only the tighter-binding S diastereomer was observed in
the enzyme-inhibitor complex. To verify these results, we
built a model of the R diastereomer, maintaining all other
contacts between the inhibitor and protein. After restraining
this configuration in several cycles ofleast squares refinement',
difference electron density maps displayed a peak of negative
density in the position of the hydroxyl group of the R diaste-
reomer and a positive peak in the region where the hydrogen
atom would be (the position of the hydroxyl group in the S
diastereomer). This confirmed that only the S diastereomer
was observed in the enzyme-inhibitor complex.
In addition to the contact between the hydroxyl group on the
tetrahedral carbon and the active site aspartates, polar contact
between inhibitor and enzyme was made through only one
substituent atom of the Asn-203 side chain (P2) (Fig. 2); it is
201 -Se r
203-Asn
0.02
0.06
0.05
0.02
0.21
0.22
0.26
0.26
1.2
1.9
3.5
4.8
2.4
21.9
14.8
Target values (weights) used in PROFFT are given as well as the
rms deviations from ideality.
205-Pro
207-Val
202-Leu Pi
P2
204-Phe P.
P1
206- Ile P-
FIG. 1. Model of the inhibitor JG-365 superimposed on the (21FO1
- IFCI)aC electron density contoured at the 1-oa level. The residues are
labeled (P4-P3) from the amino to carboxyl terminus, with the HEA
linkage at the P1-Pj junction.
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FIG. 2. Schematic representation of the hydrogen bond interactions among the inhibitor JG-365, the protein, and the solvent. Wat, water.
currently modeled as oxygen. There was no density present
for the Ser-201 (P4) hydroxyl group so it was positioned to
optimize contacts. The oxygens ofthe N-terminal acetyl group
and the C-terminal methoxy group hydrogen bond with water
molecules (Fig. 2) and the carbonyl oxygen of the methoxy
group makes contact with the nitrogen of Gly-148 (a similar
contact was made through only a water molecule in the
protease-MVT-101 complex). The C-terminal amide nitrogen
of PN in MVT-101 is not present in JG-365 so the contact
between the inhibitor and side chain of Asp-129 is lost.
The anchoring hydrogen bonds between the JG-365 inhib-
itor backbone atoms and the protein are similar to those
reported for the protease-MVT-101 structure (4), although
JG-365 is one amino acid longer on the N-terminal end.
Torsion angles for the backbone ofJG-365 are listed in Table
2. Fig. 3 shows the superposition of JG-365 and MVT-101.
The rms difference in a-carbon positions ofthe two inhibitors
is 0.56 A; for main-chain atoms the difference is 0.78 A. The
major difference in the main chains is seen at the P1-P1
linkage site. There are only subtle differences between hy-
drophobic contacts of the protease-JG-365 complex and
those of the protease-MVT-101 complex (4).
Water-301, located between the flaps and the inhibitor (Fig.
2), plays a critically important role in the interactions be-
tween the enzyme and inhibitors bound at the active site.
Water-301 was also observed in the protease-MVT-101 com-
plex (water-511). Its role appears to be important in inducing
the fit of the flaps over the inhibitor. The carbonyls of
inhibitor residues 203 and 205 are hydrogen bond acceptors
of water-301 and two main-chain nitrogen atoms from the
Table 2. Torsion angles for JG-365
Backbone dihedral angles,
deg
Residue w4
201 -64 169 180
202 -123 138 -178
203 -143 104 180
204 -94 47 151, -12
205 -57 174 175
206 -130 122 -177
207 -143 138
Backbone dihedral angles for JG-365 in the enzyme-inhibitor
complex are listed. With the exception of the HEA linkage (residues
204-205), these angles correspond to an extended conformation of
peptide.
flaps are hydrogen bond donors, resulting in tetrahedral
coordination of the water. This water molecule may help to
maintain asymmetry in the protein molecule as it mediates
the contact between the tips of the flaps and the inhibitor.
Although the HIV-1 protease dimer in the enzyme-
inhibitor complex is composed of identical polypeptide
chains, the perfect twofold symmetry present in the unli-
ganded enzyme (2) is lost. Deviations from ideal twofold
symmetry may arise in part because the inhibitor is inherently
asymmetric. Large differences are observed at the interdimer
interface that are believed to be caused by intermolecular
crystal contacts between the asymmetric protein dimers. Fig.
4 shows the positional differences in the a carbons of the two
monomers.
The regions of notable deviations between the two mono-
mers appear to be directly related to inhibitor binding. One of
these regions is the loop 49-52 (Fig. 5); the difference
between the a carbons upon superposition of Gly-49 and
P4
P1
PI1
P2
P3
FIG. 3. Superposition of the heptapeptide inhibitor JG-365 and
the hexapeptide reduced-peptide bond inhibitor MVT-101. The RIGID
option in FRODO (28) was used to superimpose the P3-P3 a-carbon
atoms of these inhibitors. Only JG-365 has a residue (serine) at
position P4.
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FIG. 4. Superposition of the a carbons of monomer 2 (dashed line) on monomer 1 (solid line) relative to the all-atom model of JG-365. The
amino and carboxyl termini of the protein are labeled (1 and 99) and the regions of significant differences are identified with a reference label
on a residue within that region. The short segments (solid line) to the left of the protease are those regions of a symmetry-related molecule that
affect the positions of the loops through crystal-packing interactions. These are identified by a symbol (#) by the reference point. It should be
noted that the symmetry-related subunit adjacent to monomer 1 is monomer 2.
Gly-149 is 1.6 A. These loop regions are the tips of the flaps
that close over the inhibitor and provide some side-chain
contacts to the hydrophobic binding pockets. It has been
pointed out (4) that these flaps rearrange themselves with
respect to the native protease and close over the inhibitor
such that the two flaps have very similar positions. The
positions are not equivalent because the peptide bond be-
tween residues Ile-50 and Gly-51 is turned 1800 compared
with that between Ile-150 and Gly-151. This provides a means
for a direct hydrogen bond between the tips of the flaps. Fig.
5 depicts the resulting positional differences in the loose loop
regions of residues 79-81 and 179-181. This region appears
to be different from one monomer to the other because the
flap peptide bond orientations are different. Loop 79-81 is in
contact with loop 149-152 through water-312. Loop 149-152
is then in a direct stabilizing contact with loop 49-52. Loop
49-52 hydrogen bonds to water-342 and makes no contacts
with loop 179-181, because its conformation is and must be
different from loop 149-152 to fit tightly over the inhibitor. It
may be significant that there are crystal lattice contacts
between the side chains of the flaps and side chains of the
adjacent symmetry-related molecule. However, it cannot be
proven whether the observed changes addressed above are
due to inhibitor binding or to crystal lattice contacts.
The largest differences in a-carbon positions between
monomer 1 and monomer 2 are along the f3 loop of residues
15-18 and the loose loop 37-40 (Fig. 4); these differences are
probably due to crystal packing. Each of these loops packs
against its own symmetry mate, mutually but not identically
affecting the conformation of the residues in the loops. The
temperature factors in these regions are the highest in the
whole protein structure, with loop 15-18 having higher
temperature factors in monomer 2 but loop 37-40 having
higher temperature factors in monomer 1.
DISCUSSION
Analysis of the structure of the complex between HIV-1
protease and JG-365, in comparison with the weaker-binding
inhibitor MVT-101 (4), provides some rationale for the tight
binding associated with JG-365. The major difference be-
tween the two inhibitors is the interaction of the hydroxyl
group in JG-365 with the catalytically active Asp-25 and
Asp-125 carboxyl groups. This hydroxyl group is known to be
critically important to binding since JG-365 binds to protease
>103- to -104-fold tighter than closely related inhibitors that
lack the hydroxyl group (9). The remaining hydrogen bonds
for both inhibitors, especially those involving the backbone
amide bonds, are very similar.
The HEA dipeptidyl unit differs from a true isosteric
analog of a reaction intermediate in substrate hydrolysis by
the presence of one extra backbone atom contained in the
methylene adjacent to the CH(OH) group. The added meth-
ylene group must be accommodated by the enzyme, and this
structure reveals that the added methylene requires the
inhibitor to adopt a conformation of P' not directly analogous
to that of MVT-101. The inhibitor backbone is kinked so that
the P1 proline ring is pushed deep into the S; binding pocket
(Fig. 3). In this regard, the proline residue is acting more as
a hydrophobic side chain than as a normal peptide unit.
However, this binding mode must be quite favorable. It is
also evident from the electron density maps that the proline
ring not contained in a true amide bond is distorted relative
to a normal puckered conformation for proline.
It is particularly interesting that only the S diastereomer of
JG-365 is seen in the crystal structure. This is consistent with
the finding that the S analogs ofJG-365 are much more potent
inhibitors of protease than the corresponding R diastere-
omers (D.H.R. and C. Q. Sun, unpublished results). These
results contrast with those of Roberts et al. (14) who found a
2-fold preference for binding of the R diastereomer of mod-
erate HEA inhibitors that span the P3-P" residues; however,
a large difference in Ki was observed between the diastere-
omers of an optimized inhibitor: the R diastereomer of the
Phe-PIC (where PIC is piperidine-(2S)-carbonyl) HEA ana-
logue was 235-fold more potent than the S diastereomer.
R
05071
Wat34 N51-
a 0739
Wat 312
FIG. 5. Stereo view of only those regions of the protease that are apparently directly affected by binding of JG-365. The dashed lines repre-
sent hydrogen bonds. The relevant backbone atoms and water molecules involved are labeled. The distance between 0-179 and 0-342 is 4.3 A.
Wat, water.
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These inhibitors lack a P3 substituent, whereas it is the
incorporation of P' into JG-365 that leads to a 600-fold
increase in its binding to the protease (22). Furthermore, in
the protease-JG-365 and protease-MVT-101 complexes, the
P' side chain of the inhibitor forms the outer wall of the S'
hydrophobic binding pocket. The absence of the P' moiety
could account for the weakened binding of JG-365 analogs
that lack the P' functionality; it might also allow alternative
tight-binding modes for inhibitors with the R configuration in
the HEA linkage.
We can use the structure ofthe protease-JG-365 complex to
examine possible contributions to the catalytic mechanism for
this aspartic protease and to see if this offers insight for the
design ofprotease inhibitors. Ifwe assume that the HEA group
mimics a reaction pathway intermediate, we can superimpose
the gem diol group of a tetrahedral intermediate over the
CH(OH) group in the HEA unit and place the proline nitrogen
in the position ofthe methylene carbon in the HEA unit, where
it would be found in the substrate. In this position, the proline
nitrogen, which approaches tetrahedral geometry as the adja-
cent carbonyl group loses trigonal planar character, lies about
3.1 A from the outer A oxygen of Asp-25. Our model is
consistent with the features of the aspartic protease general
acid-general base catalytic mechanism proposed by Suguna et
al. (23). This means that the hydroxyl group on the tetrahedral
carbon of JG-365 represents the position of the nucleophile,
assuming that attack came from that water in the active site of
the native enzyme that was seen in the structure of protease
from Rous sarcoma virus (29).
The major difference between the structures ofcomplexes of
HIV-1 protease and inhibitors and those of cell-encoded aspar-
tic proteases and inhibitors (23, 30) lies in the role of water-301.
This water molecule, which is present in both HIV-1 protease-
inhibitor complexes, serves to mediate hydrogen bonds be-
tween the two flaps and the inhibitors. Ifwater-301 exists in the
protease-substrate complexes as well, it would establish hy-
drogen bonds between the enzyme flaps and the substrate. The
resulting hydrogen bonds would exert strain on the scissile
amide bond, causing it to rotate out of plane and lose double-
bond character. These interactions would significantly enhance
the vulnerability ofthe P1-Pj bond toward hydrolysis, providing
a means for the strain (31) necessary for the proposed mecha-
nism (23). Because the Pro-205 nitrogen of the substrate would
be within hydrogen bonding distance of the outer A oxygen of
Asp-25, this would further stabilize the strained intermediate.
The presence of water-301 suggests that it should be possible to
develop selective inhibitors for retroviral proteases that require
this structural feature, which would lead to more selective
therapeutic agents.
We thank Annaliese Palmer for providing computed coordinate
sets for JG-365. The Advanced Scientific Computing Laboratory
(Frederick Cancer Research and Development Center) provided a
substantial allocation of time on their CRAY X-MP supercomputer.
Research sponsored in part by the National Cancer Institute (De-
partment of Health and Human Services) Contract NO1-CO-74101
with ABL, by funds from the National Science Foundation Biological
Instrumentation Division to S.B.H.K., and by National Institutes of
Health Grant A127302 to D.H.R.
1. Navia, M. A., Fitzgerald, P. M. D., McKeever, B. M., Leu, C.-T.,
Heimback, J. C., Herber, W. K., Sigal, I. S., Darke, P. L. &
Springer, J. P. (1989) Nature (London) 337, 615-620.
2. Wlodawer, A., Miller, M., Jask6lski, M., Sathyanarayana, B. K.,
Baldwin, E., Weber, I. T., Selk, L. M., Clawson, L., Schneider, J.
& Kent, S. B. H. (1989) Science 245, 616-621.
3. Lapatto, R., Blundell, T., Hemmings, A., Overington, J., Wilder-
spin, A., Wood, S., Merson, J. R., Whittle, P. J., Danley, D. E.,
Geoghegan, K. F., Hawrylik, S. J., Lee, S. E., Scheld, K. G. &
Hobart, P. M. (1989) Nature (London) 342, 299-302.
4. Miller, M., Schneider, J., Sathyanarayana, B. K., Toth, M. V.,
Marshall, G. R., Clawson, L., Selk, L., Kent, S. B. H. &
Wlodawer, A. (1989) Science 246, 1149-1152.
5. Pearl, L. H. & Taylor, W. R. (1987) Nature (London) 329, 351-354.
6. Seelmeier, S., Schmidt, H., Turk, V. & von der Helm, K. (1988)
Proc. Natl. Acad. Sci. USA 85, 6612-6616.
7. Mous, J., Heimer, E. P. & Le Grice, S. F. J. (1988) J. Virol. 62,
1433-1436.
8. Moore, M. L., Bryan, W. M., Fakhoury, S. A., Magaard, V. W.,
Huffman, W. F., Dayton, B. D., Meek, T. D., Hyland, L., Dreyer,
G. B., Metcalf, B. W., Strickler, J. E., Gorniak, J. G. & Debouck,
C. (1989) Biochem. Biophys. Res. Commun. 159, 420-425.
9. Dreyer, G. B., Metcalf, B. W., Tomaszek, T. A., Jr., Carr, T. J.,
Chandler, A. C., III, Hyland, L., Fakhoury, S. A., Magaard,
V. W., Moore, M. L., Strickler, J. E., Debouck, C. & Meek, T. D.
(1989) Proc. Natl. Acad. Sci. USA 86, 9752-9756.
10. Sigal, I. S., Huff, J. R., Darke, P. L., Vacca, J. P., Young, S. D.,
Desolms, J. S., Thompson, W. J., Lyle, T. A., Graham, S. L. &
Ghosh, A. K. (1989) Eur. Patent Appl. 0,337,714.
11. Billich, S., Knoop, M.-T., Hansen, J., Strop, P., Sedlacek, J.,
Mertz, R. & Moelling, K. (1988) J. Biol. Chem. 263, 17905-17908.
12. Meek, T. D., Lambert, D. M., Dreyer, G. B., Carr, T. J., To-
maszek, T. A., Jr., Moore, M. L., Strickler, J. E., Debouck, C.,
Hyland, L. J., Matthews, T. J., Metcalf, B. W. & Petteway, S. R.
(1990) Nature (London) 343, 90-92.
13. McQuade, T. J., Tomasselli, A. G., Liu, L., Karacostas, V., Moss,
B., Sawyer, T. K., Heinrickson, R. L. & Tarpley, W. G. (1990)
Science 247, 454-456.
14. Roberts, N. A., Martin, J. A., Kinchington, D., Broadhurst, A. V.,
Craig, J. C., Duncan, I. B., Galpin, S. A., Handa, B. K., Kay, J.,
Krohn, A., Lambert, R. W., Merrett, J. H., Mills, J. S., Parkes,
K. E. B., Redshaw, S., Ritchie, A. J., Taylor, D. L., Thomas, G. J.
& Machin, P. J. (1990) Science 248, 358-361.
15. Rich, D. H. (1988) in Research Monographs in Cell and Tissue
Physiology, eds. Barrett, A. J. & Salvesen, G. (Elsevier, Amster-
dam), Vol. 12, pp. 179-217.
16. Rich, D. H. (1990) in Comprehensive Medicinal Chemistry, ed.
Sammes, P. G. (Pergamon, Oxford), Vol. 2, pp. 391-441.
17. Greenlee, W. (1987) Pharm. Res. 4, 364-374.
18. Szelke, M., Leckie, B., Hallett, A., Jones, D. M., Sueiras, J.,
Atrash, B. & Lever, A. F. (1982) Nature (London) 299, 555-557.
19. Szelke, M., Jones, D. M., Atrash, B. & Hallett, A. (1983) Pept.
Struct. Funct. Proc. Am. Symp. 8th, 579-583.
20. Dann, J. G., Stammers, D. K., Harris, C. J., Arrowsmith, R. J.,
Davies, D. E., Hardy, G. W. & Morton, J. A. (1986) Biochem.
Biophys. Res. Commun. 134, 71-77.
21. Ryono, D. E., Free, C. A., Neubeck, R., Samaniego, S. G., God-
frey, J. D. & Petrillo, E. W. (1985) Pept. Struct. Funct. Proc. Am.
Pept. Symp. 9th, 739-742.
22. Rich, D. H., Green, J., Toth, M. V., Marshall, G. R. & Kent,
S. B. H. (1990) J. Med. Chem. 33, 1285-1288.
23. Suguna, K., Padlan, E. A., Smith, C. W., Carlson, W. D. & Davies,
D. R. (1987) Proc. Natl. Acad. Sci. USA 84, 7009-7013.
24. Kent, S. B. H. (1988) Annu. Rev. Biochem. 57, 957-989.
25. Schneider, J. & Kent, S. B. H. (1988) Cell 54, 363-368.
26. Hendrickson, W. A. (1985) Methods Enzymol. 115, 252-270.
27. Finzel, B. C. (1987) J. Appl. Crystallogr. 20, 53-55.
28. Jones, T. A. (1978) J. Appl. Crystallogr. 11, 268-272.
29. Miller, M., Jask6lski, M., Rao, J. K. M., Leis, J. & Wlodawer, A.
(1989) Nature (London) 337, 576-579.
30. Blundell, T. L., Cooper, J., Foundling, S. I., Jones, D. M., Atrash,
B. & Szelke, M. (1987) Biochemistry 26, 5585-5590.
31. Jencks, W. P. (1969) in Catalysis in Chemistry and Enzymology
(McGraw-Hill, New York), pp. 294-308.
Biochemistry: Swain et al.
